HomeInsightsStock Comparison

Biocon Ltd vs Shilpa Medicare Ltd Stock Comparison

Biocon Ltd vs Shilpa Medicare Ltd Stock Comparison

Last Updated on: Aug 09, 2025

Key Highlights

  • The Latest Trading Price of Biocon Ltd is ₹ 356.85 as of 07 Aug 13:53.
  • The P/E Ratio of Biocon Ltd changed from 43.4 on March 2020 to 40.4 on March 2025 . This represents a CAGR of -1.19% over 6 yearsThe P/E Ratio of Shilpa Medicare Ltd changed from 12.8 on March 2020 to 0 on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The Market Cap of Biocon Ltd changed from ₹ 32472 crore on March 2020 to ₹ 40964 crore on March 2025 . This represents a CAGR of 3.95% over 6 yearsThe Market Cap of Shilpa Medicare Ltd changed from ₹ 1993 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 6 years.
  • The revenue of Biocon Ltd for the Jun '25 is ₹ 4021 crore as compare to the Mar '25 revenue of ₹ 4474 crore. This represent the decline of -10.12% The revenue of Shilpa Medicare Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 340.68 crore. This represent the decline of -100%.
  • The ebitda of Biocon Ltd for the Jun '25 is ₹ 828.6 crore as compare to the Mar '25 ebitda of ₹ 1135 crore. This represent the decline of -27.03% The ebitda of Shilpa Medicare Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 58.56 crore. This represent the decline of -100%.
  • The net profit of Biocon Ltd changed from ₹ 148.9 crore to ₹ 89.2 crore over 9 quarters. This represents a CAGR of -20.37% The net profit of Shilpa Medicare Ltd changed from ₹ 1.18 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% .
  • The Dividend Payout of Biocon Ltd changed from 69.72 % on March 2022 to 9.85 % on March 2025 . This represents a CAGR of -38.69% over 4 yearsThe Dividend Payout of Shilpa Medicare Ltd changed from 4.63 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Biocon Ltd

  • Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company.
  • At present, Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw.
  • Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind.
  • In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International.
  • Also in the same year, the company had received US funding for proprietary technologies.

About Shilpa Medicare Ltd

  • Shilpa Medicare Limited (Formerly known as Shilpa Antibiotics Private Limited) was incorporated as a Private Limited Company on November 20, 1987.
  • The Company changed the status to Public Limited and the name of the Company was changed to Shilpa Antibiotics Limited in November, 1993 and later on, was changed to 'Shilpa Medicare Limited' on February 17, 2003. The Company has been promoted by Vishnukant C. Bhutada and his Associates and is engaged in manufacturing of API, Formulation and Development service.
  • The Company started its operations as API manufacturer way back in 1987 at Raichur, Karnataka.
  • It then started commercial production in November, 1989. The Company is one of the leading API and formulations manufacturers with strong capabilities in the therapeutic area of oncology.

Biocon Ltd News Hub

News

Biocon drops after Q1 PAT tumbles 95% YoY to Rs 31 cr

Profit before tax (PBT) dropped 91.5% to Rs 96.90 crore in Q1 FY26 compared with Rs 1145.5...

Read more

08 Aug 2025 10:28

News

Biocon Ltd slips for fifth straight session

Biocon Ltd dropped for a fifth straight session today. The stock is quoting at Rs 372.85, ...

Read more

05 Aug 2025 13:35

News

Biocon edges higher after biologics arm launches autoimmune treatment drug Nepexto in Australia

Nepexto will be promoted by Generic Health, BBL's local partner and a leading provider of ...

Read more

23 Jul 2025 10:33

News

Biocon arm gets USFDA approval for insulin, Kirsty

Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to im...

Read more

16 Jul 2025 08:32

News

Biocon Ltd gains for third straight session

Biocon Ltd gained for a third straight session today. The stock is quoting at Rs 390, up 2...

Read more

15 Jul 2025 13:05

News

Biocon schedules board meeting

Biocon will hold a meeting of the Board of Directors of the Company on 7 August 2025. Powe...

Read more

09 Jul 2025 10:55

Shilpa Medicare Ltd News Hub

News

Shilpa Medicare to hold board meeting

Shilpa Medicare will hold a meeting of the Board of Directors of the Company on 13 August ...

Read more

06 Aug 2025 15:09

News

Shilpa Medicare Ltd Falls 4.48%, BSE Healthcare index Drops 1.93%

Shilpa Medicare Ltd lost 4.48% today to trade at Rs 876.5. The BSE Healthcare index is dow...

Read more

31 Jul 2025 09:30

News

Shilpa Medicare's Unit VI clears USFDA inspection

Shilpa Medicare announced that its Unit VI, Dabaspet, Bengaluru, has received EIR with VAI...

Read more

16 Jul 2025 10:10

News

Shilpa Medicare gains as unit VI gets USFDA EIR with VAI classification

The good manufacturing practice (GMP) inspection was conducted from 24 October 2024 to 30 ...

Read more

16 Jul 2025 11:25

News

Shilpa Medicare's Unit VI facility receives SFDA, Saudi Arabia GMP certification

Shilpa Medicare's Unit VI facility, located at Dabaspet, Bengaluru, Karnataka, has receive...

Read more

10 Jul 2025 14:22

News

Shilpa Medicare gains on receiving SFDA GMP certification for Bengaluru facility

The certification follows an on-site inspection conducted from 18 February to 20 February ...

Read more

10 Jul 2025 13:23

SWOT Analysis Of Biocon Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Shilpa Medicare Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Biocon Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Shilpa Medicare Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Biocon Ltd and Shilpa Medicare Ltd

Which company has a larger market capitalization, Biocon Ltd or Shilpa Medicare Ltd?

Market cap of Biocon Ltd is 45,904 Cr while Market cap of Shilpa Medicare Ltd is 8,134 Cr

What are the key factors driving the stock performance of Biocon Ltd and Shilpa Medicare Ltd?

The stock performance of Biocon Ltd and Shilpa Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Biocon Ltd and Shilpa Medicare Ltd?

As of August 9, 2025, the Biocon Ltd stock price is INR ₹343.35. On the other hand, Shilpa Medicare Ltd stock price is INR ₹831.8.

How do dividend payouts of Biocon Ltd and Shilpa Medicare Ltd compare?

To compare the dividend payouts of Biocon Ltd and Shilpa Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions